These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30911879)

  • 1. Understanding drug-drug interaction and pharmacogenomic changes in pharmacokinetics for metabolized drugs.
    Benet LZ; Bowman CM; Koleske ML; Rinaldi CL; Sodhi JK
    J Pharmacokinet Pharmacodyn; 2019 Apr; 46(2):155-163. PubMed ID: 30911879
    [TBL] [Abstract][Full Text] [Related]  

  • 2. How Transporters Have Changed Basic Pharmacokinetic Understanding.
    Benet LZ; Bowman CM; Sodhi JK
    AAPS J; 2019 Sep; 21(6):103. PubMed ID: 31482335
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Improved Human Pharmacokinetic Prediction of Hepatically Metabolized Drugs With Species-Specific Systemic Clearance.
    Horiuchi K; Ohnishi S; Matsuzaki T; Funaki S; Watanabe A; Mizutare T; Matsumoto S; Nezasa KI; Hasegawa H
    J Pharm Sci; 2018 May; 107(5):1443-1453. PubMed ID: 29331382
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Extended Clearance Concept Following Oral and Intravenous Dosing: Theory and Critical Analyses.
    Benet LZ; Bowman CM; Liu S; Sodhi JK
    Pharm Res; 2018 Oct; 35(12):242. PubMed ID: 30349948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of chronic renal failure on the disposition of highly hepatically metabolized drugs.
    Yuan R; Venitz J
    Int J Clin Pharmacol Ther; 2000 May; 38(5):245-53. PubMed ID: 10839468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chirality and pharmacokinetics: an area of neglected dimensionality?
    Hutt AJ
    Drug Metabol Drug Interact; 2007; 22(2-3):79-112. PubMed ID: 17708062
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Drug dosing in chronic hepatic disease (author's transl)].
    Gugler R; Eichelbaum M
    Leber Magen Darm; 1981 Apr; 11(2):81-7. PubMed ID: 7015045
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Single- and multiple-dose mibefradil pharmacokinetics in normal and hypertensive subjects.
    Welker HA
    J Pharm Pharmacol; 1998 Sep; 50(9):983-7. PubMed ID: 9811158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetic parameters: which are necessary to define a drug substance?
    Benet LZ
    Eur J Respir Dis Suppl; 1984; 134():45-61. PubMed ID: 6586486
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Presystemic extraction: mechanisms and consequences.
    Greenblatt DJ
    J Clin Pharmacol; 1993 Jul; 33(7):650-6. PubMed ID: 8366190
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous assessment of drug interactions with low- and high-extraction opioids: application to parecoxib effects on the pharmacokinetics and pharmacodynamics of fentanyl and alfentanil.
    Ibrahim AE; Feldman J; Karim A; Kharasch ED
    Anesthesiology; 2003 Apr; 98(4):853-61. PubMed ID: 12657846
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cilostazol pharmacokinetics after single and multiple oral doses in healthy males and patients with intermittent claudication resulting from peripheral arterial disease.
    Bramer SL; Forbes WP; Mallikaarjun S
    Clin Pharmacokinet; 1999; 37 Suppl 2():1-11. PubMed ID: 10702882
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-independent pharmacokinetics of the cardioprotective agent dexrazoxane in dogs.
    Baldwin JR; Lewis RC; Phillips BA; Overmyer SK; Hatfield NZ; Narang PK
    Biopharm Drug Dispos; 1996 Aug; 17(6):541-50. PubMed ID: 8866044
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-compartmental analysis of pharmacokinetic data after multiple intravenous and oral administration.
    Rohatagi S; Kan S; Derendorf H
    Pharmazie; 1997 Jul; 52(7):529-32. PubMed ID: 9266589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prediction of human pharmacokinetics using physiologically based modeling: a retrospective analysis of 26 clinically tested drugs.
    De Buck SS; Sinha VK; Fenu LA; Nijsen MJ; Mackie CE; Gilissen RA
    Drug Metab Dispos; 2007 Oct; 35(10):1766-80. PubMed ID: 17620347
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Commentary: a physiological approach to hepatic drug clearance.
    Wilkinson GR; Shand DG
    Clin Pharmacol Ther; 1975 Oct; 18(4):377-90. PubMed ID: 1164821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Benzodiazepine drug-drug interactions commonly occurring in clinical practice.
    Abernethy DR; Greenblatt DJ; Ochs HR; Shader RI
    Curr Med Res Opin; 1984; 8 Suppl 4():80-93. PubMed ID: 6144465
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prediction of drug terminal half-life and terminal volume of distribution after intravenous dosing based on drug clearance, steady-state volume of distribution, and physiological parameters of the body.
    Berezhkovskiy LM
    J Pharm Sci; 2013 Feb; 102(2):761-71. PubMed ID: 23233148
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaprozin and piroxicam, nonsteroidal antiinflammatory drugs with long half-lives: effect of protein-binding differences on steady-state pharmacokinetics.
    Karim A; Noveck R; McMahon FG; Smith M; Crosby S; Adams M; Wilton J
    J Clin Pharmacol; 1997 Apr; 37(4):267-78. PubMed ID: 9115051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients.
    Kuypers DR; Claes K; Evenepoel P; Maes B; Coosemans W; Pirenne J; Vanrenterghem Y
    Clin Pharmacokinet; 2004; 43(11):741-62. PubMed ID: 15301578
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.